ADMA Biologics ADMA Pre-Tax Income (Domestic)
Pre-Tax Income (Domestic) at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic.
The official record: ADMA Biologics’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →
Ask your AI about ADMA Biologics's pre-tax income (domestic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ADMA Biologics's pre-tax income (domestic)?
- ADMA Biologics (ADMA) reported pre-tax income (domestic) of $45.66M in Q4 2025.
- How has ADMA Biologics's pre-tax income (domestic) changed year-over-year?
- ADMA Biologics's pre-tax income (domestic) increased by 45.3% year-over-year, from $31.43M to $45.66M.
- What is the long-term trend for ADMA Biologics's pre-tax income (domestic)?
- Over 2 years (2023 to 2025), ADMA Biologics's pre-tax income (domestic) has grown at a 154.3% compound annual growth rate (CAGR), from -$28.24M to $182.66M.
- What does pre-tax income (domestic) mean?
- Represents the profit or loss generated from domestic business operations before accounting for income tax expenses. This metric isolates the core operational performance within the home country, excluding foreign earnings and tax-related adjustments. It serves as a key indicator of the company's domestic profitability and operational efficiency.